Publication

Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome

Matas-Rico, E., van Veen, M., Leyton-Puig, D., van den Berg, J., Koster, J., Kedziora, K. M., Molenaar, B., Weerts, M. J. A., de Rink, I., Medema, R. H., Giepmans, B. N. G., Perrakis, A., Jalink, K., Versteeg, R. & Moolenaar, W. H., 10-Oct-2016, In : Cancer cell. 30, 4, p. 548-562 15 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Matas-Rico, E., van Veen, M., Leyton-Puig, D., van den Berg, J., Koster, J., Kedziora, K. M., ... Moolenaar, W. H. (2016). Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. Cancer cell, 30(4), 548-562. https://doi.org/10.1016/j.ccell.2016.08.016

Author

Matas-Rico, Elisa ; van Veen, Michiel ; Leyton-Puig, Daniela ; van den Berg, Jeroen ; Koster, Jan ; Kedziora, Katarzyna M. ; Molenaar, Bas ; Weerts, Marjolein J. A. ; de Rink, Iris ; Medema, Rene H. ; Giepmans, Ben N. G. ; Perrakis, Anastassis ; Jalink, Kees ; Versteeg, Rogier ; Moolenaar, Wouter H. / Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. In: Cancer cell. 2016 ; Vol. 30, No. 4. pp. 548-562.

Harvard

Matas-Rico, E, van Veen, M, Leyton-Puig, D, van den Berg, J, Koster, J, Kedziora, KM, Molenaar, B, Weerts, MJA, de Rink, I, Medema, RH, Giepmans, BNG, Perrakis, A, Jalink, K, Versteeg, R & Moolenaar, WH 2016, 'Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome', Cancer cell, vol. 30, no. 4, pp. 548-562. https://doi.org/10.1016/j.ccell.2016.08.016

Standard

Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. / Matas-Rico, Elisa; van Veen, Michiel; Leyton-Puig, Daniela; van den Berg, Jeroen; Koster, Jan; Kedziora, Katarzyna M.; Molenaar, Bas; Weerts, Marjolein J. A.; de Rink, Iris; Medema, Rene H.; Giepmans, Ben N. G.; Perrakis, Anastassis; Jalink, Kees; Versteeg, Rogier; Moolenaar, Wouter H.

In: Cancer cell, Vol. 30, No. 4, 10.10.2016, p. 548-562.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Matas-Rico E, van Veen M, Leyton-Puig D, van den Berg J, Koster J, Kedziora KM et al. Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. Cancer cell. 2016 Oct 10;30(4):548-562. https://doi.org/10.1016/j.ccell.2016.08.016


BibTeX

@article{332e3ba4f0cb47459d00a0c930791f9c,
title = "Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome",
abstract = "Neuroblastoma is a pediatric embryonal malignancy characterized by impaired neuronal differentiation. A better understanding of neuroblastoma differentiation is essential for developing new therapeutic approaches. GDE2 (encoded by GDPD5) is a six-transmembrane-domain glycerophosphodiesterase that promotes embryonic neurogenesis. We find that high GDPD5 expression is strongly associated with favorable outcome in neuroblastoma. GDE2 induces differentiation of neuroblastoma cells, suppresses cell motility, and opposes RhoA-driven neurite retraction. GDE2 alters the Rac-RhoA activity balance and the expression of multiple differentiation-associated genes. Mechanistically, GDE2 acts by cleaving (in cis) and releasing glycosylphosphatidylinositol-anchored glypican-6, a putative co-receptor. A single point mutation in the ectodomain abolishes GDE2 function. Our results reveal GDE2 as a cell-autonomous inducer of neuroblastoma differentiation with prognostic significance and potential therapeutic value.",
keywords = "HIGH-RISK NEUROBLASTOMA, LYSOPHOSPHATIDIC ACID, HEPATOCELLULAR-CARCINOMA, NEURONAL DIFFERENTIATION, NEURITE RETRACTION, MEMBRANE-PROTEIN, RHO-GTPASES, PHOSPHODIESTERASE, CELLS, INHIBITION",
author = "Elisa Matas-Rico and {van Veen}, Michiel and Daniela Leyton-Puig and {van den Berg}, Jeroen and Jan Koster and Kedziora, {Katarzyna M.} and Bas Molenaar and Weerts, {Marjolein J. A.} and {de Rink}, Iris and Medema, {Rene H.} and Giepmans, {Ben N. G.} and Anastassis Perrakis and Kees Jalink and Rogier Versteeg and Moolenaar, {Wouter H.}",
note = "Copyright {\circledC} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = "10",
day = "10",
doi = "10.1016/j.ccell.2016.08.016",
language = "English",
volume = "30",
pages = "548--562",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "CELL PRESS",
number = "4",

}

RIS

TY - JOUR

T1 - Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome

AU - Matas-Rico, Elisa

AU - van Veen, Michiel

AU - Leyton-Puig, Daniela

AU - van den Berg, Jeroen

AU - Koster, Jan

AU - Kedziora, Katarzyna M.

AU - Molenaar, Bas

AU - Weerts, Marjolein J. A.

AU - de Rink, Iris

AU - Medema, Rene H.

AU - Giepmans, Ben N. G.

AU - Perrakis, Anastassis

AU - Jalink, Kees

AU - Versteeg, Rogier

AU - Moolenaar, Wouter H.

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/10/10

Y1 - 2016/10/10

N2 - Neuroblastoma is a pediatric embryonal malignancy characterized by impaired neuronal differentiation. A better understanding of neuroblastoma differentiation is essential for developing new therapeutic approaches. GDE2 (encoded by GDPD5) is a six-transmembrane-domain glycerophosphodiesterase that promotes embryonic neurogenesis. We find that high GDPD5 expression is strongly associated with favorable outcome in neuroblastoma. GDE2 induces differentiation of neuroblastoma cells, suppresses cell motility, and opposes RhoA-driven neurite retraction. GDE2 alters the Rac-RhoA activity balance and the expression of multiple differentiation-associated genes. Mechanistically, GDE2 acts by cleaving (in cis) and releasing glycosylphosphatidylinositol-anchored glypican-6, a putative co-receptor. A single point mutation in the ectodomain abolishes GDE2 function. Our results reveal GDE2 as a cell-autonomous inducer of neuroblastoma differentiation with prognostic significance and potential therapeutic value.

AB - Neuroblastoma is a pediatric embryonal malignancy characterized by impaired neuronal differentiation. A better understanding of neuroblastoma differentiation is essential for developing new therapeutic approaches. GDE2 (encoded by GDPD5) is a six-transmembrane-domain glycerophosphodiesterase that promotes embryonic neurogenesis. We find that high GDPD5 expression is strongly associated with favorable outcome in neuroblastoma. GDE2 induces differentiation of neuroblastoma cells, suppresses cell motility, and opposes RhoA-driven neurite retraction. GDE2 alters the Rac-RhoA activity balance and the expression of multiple differentiation-associated genes. Mechanistically, GDE2 acts by cleaving (in cis) and releasing glycosylphosphatidylinositol-anchored glypican-6, a putative co-receptor. A single point mutation in the ectodomain abolishes GDE2 function. Our results reveal GDE2 as a cell-autonomous inducer of neuroblastoma differentiation with prognostic significance and potential therapeutic value.

KW - HIGH-RISK NEUROBLASTOMA

KW - LYSOPHOSPHATIDIC ACID

KW - HEPATOCELLULAR-CARCINOMA

KW - NEURONAL DIFFERENTIATION

KW - NEURITE RETRACTION

KW - MEMBRANE-PROTEIN

KW - RHO-GTPASES

KW - PHOSPHODIESTERASE

KW - CELLS

KW - INHIBITION

U2 - 10.1016/j.ccell.2016.08.016

DO - 10.1016/j.ccell.2016.08.016

M3 - Article

VL - 30

SP - 548

EP - 562

JO - Cancer cell

JF - Cancer cell

SN - 1535-6108

IS - 4

ER -

ID: 36028488